Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on August 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). CEO and Chairman Seth Lederman appointed Interim Chief Medical Officer effective August 18, 2026.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO and Chairman Seth Lederman appointed Interim Chief Medical Officer effective August 18, 2026
- Leadership consolidation adds medical oversight under the existing CEO, without changing his other roles
- No disclosed appointment arrangements or family relationships with directors or executive officers
Item 8.01 · Other Events
- Dr. Lederman appointed Interim Chief Medical Officer effective August 18, 2026
- Interim medical leadership change may affect clinical development oversight and regulatory execution
- Appointment signals a near-term CMO transition, with permanent succession details not provided
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.